Showing results (1991-2000 of 2,317) with videos related to
Sort By:
Pageof 232
Applied and Environmental Microbiology|August 14, 2012
Epidemiology of a Salmonella enterica subsp. enterica serovar Typhimurium strain associated with a songbird outbreakSonia M Hernandez, Kevin Keel, Susan Sanchez, et al.Journal of Virology|January 31, 2024
BGLF4 kinase regulates the formation of the EBV cytoplasmic assembly compartment and the recruitment of cellular IQGAP1 for virion releaseYu-Ching Dai, Szu-Yun Yeh, Yi-Ying Cheng, et al.Journal of Hematology & Oncology|January 11, 2018
Correction to: Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort studyXinyang Liu, Shukui Qin, Zhichao Wang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 7, 2013
Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trialJin Li, Shukui Qin, Jianming Xu, et al.Oncology and Therapy|June 11, 2025
Impact of Tumor Response and Response Duration on Survival Among Participants Receiving Pembrolizumab Plus Chemotherapy as First-Line Therapy for Non-Small-Cell Lung CancerMarina C Garassino, Ying Cheng, Delvys Rodriguez-Abreu, et al.Journal of Hematology & Oncology|September 6, 2017
Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort studyXinyang Liu, Shukui Qin, Zhichao Wang, et al.Gynecologic Oncology|November 30, 2020
Olaparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 mutation: SOLO1 China cohortLingying Wu, Jianqing Zhu, Rutie Yin, et al.Cancer Communications (London, England)|April 4, 2019
Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trialJing Huang, Binghe Xu, Ying Liu, et al.The Oncologist|March 24, 2019
Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical TrialAi-Ping Zhou, Yuxian Bai, Yan Song, et al.Journal of Multidisciplinary Healthcare|November 29, 2023
Impacts of Huddle Intervention on the Patient Safety Culture of Medical Team Members in Medical Ward: One-Group Pretest-Posttest DesignYi-Hung Lai, Ming-Ju Wu, Hsin-Hua Chen, et al.Pageof 232